Book a demo

Chemical intelligence powered by cypris.ai

2-(3-benzyltriazolo[4,5-d]pyrimidin-7-yl)sulfanyl-1,3-benzoxazole

2-(3-benzyltriazolo[4,5-d]pyrimidin-7-yl)sulfanyl-1,3-benzoxazole

FormulaC18H12N6OS
Mol. weight360.395
PubChem CID4058452
InChIKeyHZSOKHVVANONPV-UHFFFAOYSA-N
SMILESC1=CC=C(C=C1)CN2C3=C(C(=NC=N3)SC4=NC5=CC=CC=C5O4)N=N2
138Patents
56Research papers
52Patents - last 3 years
2Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Emory University20
2Biontech SE14
3United States Department of Health and Human Services9
4Verinos Operations GmbH7
5Astellas Pharma Inc6
6Centre National de la Recherche Scientifique5
7Beijing Tongren Hospital4
8Boehringer Ingelheim International GmbH4
9Universiteit Maastricht4
10Cincinnati Childrens Hospital Medical Center3

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61KMedicinal preparations119
2A61PTherapeutic activity (drug indications)113
3C07KPeptides35
4C12NMicroorganisms, enzymes31
5C07DHeterocyclic compounds24
6G01NInvestigating / analysing materials19
7C12QMeasuring/testing involving enzymes16
8A61QCosmetics, personal care12
9Y02AClimate change adaptation12
10C12YEnzyme nomenclature (EC numbers)10

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#Research topicPapers
1Neutrophil, Myeloperoxidase and Oxidative Mechanisms1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Bin LiuCentral South University3
2Jun PengCentral South University3
3Patricia I. OteizaUniversity of California, Davis3
4Adriana V. TreuerUniversity of Talca2
5Daniel R. GonzálezUniversity of Talca2
6Daniel SimõesUniversidade de São Paulo1
7Galina Yu. MironovaKoltzov Institute of Developmental Biology2
8Gang DaiThe First Affiliated Hospital, Sun Yat-sen University2
9Harald SchmidtMonash University2
10Jianwen ChenSun Yat-sen University2

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular composition of this compound?

2-(3-benzyltriazolo[4,5-d]pyrimidin-7-yl)sulfanyl-1,3-benzoxazole has the molecular formula C18H12N6OS with a molecular weight of 360.395 g/mol and an InChI Key of HZSOKHVVANONPV-UHFFFAOYSA-N.

Which organizations hold the most patents involving this compound?

Emory University leads with 20 patents, followed by Biontech SE with 14 patents and the US Department of Health and Human Services with 7 patents. Other significant patent holders include Verinos Operations GmbH and Astellas Pharma Inc, each with 6 patents.

What is the primary application focus based on patent classification?

The compound is predominantly classified under pharmaceutical and medical use categories, with A61K (pharmaceutical preparations) appearing in 119 patents and A61P (therapeutic applications) in 112 patents. This indicates the compound is primarily developed for pharmaceutical and therapeutic purposes.

What research topics are associated with published studies on this compound?

The most cited published work involves research on oxidative stress and vascular biology, with studies addressing topics such as Inflammasome and immune disorders, Nitric Oxide and Endothelin Effects, and mechanisms related to Neutrophil, Myeloperoxidase and Oxidative Mechanisms.

What is the recent activity trend for this compound?

Patent activity has increased significantly in recent years, with 33 patents filed in 2022 and 27 in 2024. However, publication activity has been limited in recent years, with only 2 papers published in the last 3 years. Overall, the compound has generated 138 total patents and 56 papers in the literature.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial